To further enhance the quality of the Journal of Pharmaceutical and BioTech Industry (JPBI, ISSN: 2813-9380) and the papers published in it, under the guidance of our Editor-in-Chief, Prof. Dr. Bozena B. Michniak-Kohn, the journal has updated and revised its aims and scope. The original scope and the updated version are listed below:
|
Scope (new version):
|
Scope (old version):
|
- Pharmaceuticals, biopharmaceuticals, and active pharmaceutical ingredient production;
- Early drug discovery and development;
- Product characterization and pre-clinical testing;
- Drug delivery systems and drug design;
- Formulation, device, and packaging development;
- Process development, optimization, scale-up, and manufacturing;
- Biotechnology, applied immunology, human gene therapy, and molecular diagnostics/therapeutics;
- Pharmacokinetics, pharmacodynamics, and metabolism–transport of drugs;
- Mathematical modeling, simulations, and digital twins;
- Natural products, marine biotechnology, and green chemistry;
- Toxicology;
- Clinical trials for pharmaceuticals and biopharmaceuticals;
- Patent analysis, regulatory and legislative approval issues.
|
- Early drug discovery and development;
- Product characterization and pre-clinical testing;
- Drug delivery systems and drug design;
- Active pharmaceutical ingredient (API) production;
- Formulation, device, and packaging development;
- Process development, optimization, scale-up, and manufacturing;
- Pharmaceutics and biopharmaceutics;
- Mathematical modeling, simulations, and digital twins;
- Pharmacokinetics, pharmacodynamics, and metabolism–transport of drugs;
- Pharmaceutical nanotechnology and biotechnology;
- Natural products and green chemistry;
- Toxicology;
- Clinical trials;
- Regulatory and legislative approval;
- Patent analysis.
|
For more detailed information, please visit the following link: https://www.mdpi.com/journal/jpbi/about.
JPBI Editorial Office
